QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Résumé Extracto Full Text PDF Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Articles Ahead of Print [Order Reprint] Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Cantrell, M. A Articles by Magera, J. S Search for Related Content PubMed PubMed Citation Articles by Cantrell, M. A Articles by Magera, J. S, Jr

NEW DRUG APPROVALS

Silodosin for Benign Prostatic Hyperplasia

Assistant Professor (Clinical), College of Pharmacy, University of Iowa; Clinical Pharmacy Specialist, Veterans Affairs Medical Center, Iowa City, IA

Heather R Bream-Rouwenhorst, PharmD BCPS

Assistant Professor (Clinical), College of Pharmacy, University of Iowa; Clinical Pharmacy Specialist, Veterans Affairs Medical Center

Phyllis Hemerson, PharmD

Assistant Professor (Clinical), College of Pharmacy, University of Iowa; Clinical Pharmacy Specialist, Mercy Hospital, Iowa City

James S Magera Jr, MD

Department of Surgery, Division of Urology, Mercy Hospital

Reprints: Dr. Cantrell, 601 Hwy. 6 W, Iowa City, IA 52246, fax 319/887-4951, matthew.cantrell{at}va.gov

OBJECTIVE: To review the pharmacology, pharmacokinetics, clinical trials, and safety of silodosin, a recently approved _1A-adrenergic receptor (AR) antagonist for benign prostatic hyperplasia (BPH).

DATA SOURCES: English-only articles obtained from MEDLINE (1966-October 2009) using the search terms silodosin and KMD-3213 were reviewed. In addition, a search of International Pharmaceutical Abstracts (1970-October 2009) was conducted.

STUDY SELECTION AND DATA EXTRACTION: Available English-language articles were reviewed, as well as abstracts from available non-English articles.

DATA SYNTHESIS: Silodosin reduces urinary symptoms associated with BPH in as little as 1 day after initiation. The largest clinical trial conducted to date demonstrated a decrease in International Prostate Symptom Score of -6.4 ± 6.63 points compared to -3.5 ± 5.84 in patients receiving placebo (p < 0.0001). Silodosin also improved urinary flow rates by approximately 2.8 ± 3.44 mL/sec, which is comparable to other ₁-AR antagonists. The usual dose of silodosin is 8 mg once daily and should be reduced to 4 mg for patients with moderate renal dysfunction. Use is contraindicated in patients with severe renal and hepatic impairment or taking strong CYP3A4 inhibitors. In clinical trials, the most prevalent adverse effects were ejaculatory disturbances, occurring in approximately 28% of patients, although only 2.8% of patients discontinued treatment due to this adverse effect. Preliminary data suggest that, similar to other third-generation _1A-AR antagonists, silodosin has little potential to cause significant cardiovascular adverse effects such as orthostatic hypotension or syncope. To confirm these findings, long-term studies are still needed, especially in patients taking antihypertensive agents and in those with a history of intolerance to other ₁-AR antagonists.

CONCLUSIONS: Silodosin was approved by the Food and Drug Administration in 2008. Long-term studies demonstrating improvement in clinically important outcomes of BPH have yet to be published. In addition, pharmacoeconomic analyses would assist in defining its current place in therapy. Until this information is available, silodosin may be best reserved as an alternative to other second- and third-generation ₁-AR antagonists.

Key Words: benign prostatic hyperplasia, silodosin

Published Online, January 13, 2010. www.theannals.com, DOI 10.1345/aph.1M320

THIS ARTICLE IS APPROVED FOR CONTINUING EDUCATION CREDIT
ACPE UNIVERSAL ACTIVITY NUMBER: 407-000-10-006-H01-P